logo
OCD's Origins Might Not Lie in The Brain Like We Thought

OCD's Origins Might Not Lie in The Brain Like We Thought

Yahoo08-07-2025
Obsessive-compulsive disorder (OCD) affects up to 3 percent of people worldwide and remains one of the most challenging mental health conditions to treat effectively.
That makes any fresh insight into OCD's root causes especially valuable – like a new study pointing to a surprising suspect: the bacteria living in our gut.
The research from China explored how the gut microbiota – the complex community of bacteria that live in the digestive system – may influence whether a person develops OCD, and identified six types of bacteria that appear to be linked with the condition.
A steady stream of studies has shown close connections between the brain and the gut, but this is the first to provide compelling evidence that gut bacteria may actually help cause it. The researchers used genetic data to strengthen the case for causation.
Related:
"Previous studies have indicated a potential link between the gut microbiota and OCD," write the researchers from Chongqing Medical University in their published paper. "However, the exact causal relationship remains uncertain."
"Our analysis suggested that specific gut microbiota might have a causal relationship with OCD, revealing potential intervention strategies for the prevention and treatment of this disorder."
To explore this link, the researchers used a genetic approach known as Mendelian randomization, which allows scientists to infer causality by analyzing genetic variants that influence both OCD and gut bacteria.
They assessed links between genetic data and gut bacteria in a sample of 18,340 people, and the links between genetic data and OCD in a separate sample of 199,169 people.
Although these were two discrete sets of data, the study used Mendelian randomization to essentially bridge the gap and connect gut bacteria patterns with OCD.
Because our genes are fixed at birth and not shaped by environment or lifestyle, this method helps strengthen the case that gut bacteria might directly contribute to OCD, rather than just being an effect of it.
However, more data and more controlled experiments will be needed to confirm a causal link.
Three types of bacteria appeared to be protective against OCD: Proteobacteria, Ruminococcaceae, and Bilophila. Another three seemed to increase the risk of OCD: Bacillales, Eubacterium, and Lachnospiraceae UCG001.
Interestingly, many of these bacteria have been linked with the brain before. For example, previous studies have found a connection between low levels of Ruminococcaceae species and depression. These findings expand what we already know about the gut-brain axis and how one can affect the other.
"Future research should employ longitudinal designs and diverse populations to validate and expand upon these findings, as well as a more in-depth classification of microbes and their metabolic products, to further understand the role of gut microbiota in OCD," write the researchers.
Down the line – and it's still a way off – we may have a new way to treat or prevent OCD, by controlling gut bacteria mixtures. For people living with the condition – and the families, friends, and clinicians who support them – this could eventually offer new hope.
"Despite the utilization of cognitive behavioral therapy and selective serotonin reuptake inhibitors in OCD treatment, a notable 25–40 percent of patients experience suboptimal or no response to these interventions," write the researchers.
"Moreover, the personal and societal toll of OCD is substantial."
The research has been published in the Journal of Affective Disorders.
The News Cycle Is a Stress Monster. But There's a Healthy Way to Stay Informed.
Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's
Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Colts RT Braden Smith 'in a spectacular place' after career-threatening battle with OCD
Colts RT Braden Smith 'in a spectacular place' after career-threatening battle with OCD

Indianapolis Star

time4 days ago

  • Indianapolis Star

Colts RT Braden Smith 'in a spectacular place' after career-threatening battle with OCD

WESTFIELD, Ind. — Braden Smith has been looking forward to this training camp. To this season. A chance to experience the joy of football again, freed from the stranglehold obsessive-compulsive disorder placed on him last year. A specific type of OCD, religious scrupulosity, overwhelmed Smith last year, forcing him to leave the Colts with five games left in the season in a desperate attempt to find an answer for what was going through his mind. The search took Smith through therapy, medicine, a Colorado health clinic and finally a controversial treatment with psychedelics in Mexico, but the 29-year-old right tackle emerged on the other side last spring with his OCD under control. In his own words: Colts RT Braden Smith's desperate, life-threatening fight vs OCD A half a year later, Smith is back on the practice field at Grand Park, ready to enjoy football again after his battle with OCD caused him to briefly consider retirement last fall. 'I'm in a spectacular place, honestly,' Smith said. 'I've learned a lot about myself. I've learned different tools and strategies, I've had a great support system here and at home.' When Smith returned from an ibogaine treatment in Mexico that he believes erased the bad habits his mind had created — internal compulsions that caused him to repetitively pray, repent or declare his faith — he began intensive therapy for OCD. In Smith's own words, he still has OCD. But it no longer has a hold on him, no longer serves as a crushing weight on him at all times, forcing him to try to justify himself to a perfect God. 'There's not boxes I need to check off, there's not things I need to do,' Smith said. 'It's not perfect, but it's kind of allowed me to give it all to Him and not worry about what else can happen.' Smith, a Christian who was baptized last May after deciding to devote himself fully to his faith, has found better balance in his belief, a pursuit of God based on love rather than guilt. 'You have to find out what is healthy and what is not healthy. It looks a little bit different for every person,' Smith said. 'My relationship to God doesn't have to be a cookie-cutter type of thing. … Luckily, the whole point is just (having) a relationship.' Playing football again on the practice fields at Grand Park is a reminder of how far Smith has come since last winter. One of the statements that set off alarm bells for Courtney was when Smith floated the idea of retirement last September. Her husband has always loved playing football, loved playing the game, and the OCD had stripped football of the joy and fulfillment he felt playing the game. The Colts tried to help Smith. Instead of ignoring or downplaying his symptoms, the coaching staff helped Smith find treatment and medicine, allowed the veteran right tackle to avoid going to meetings when OCD began to overtake him and supported his decision to miss the rest of the season. The day before Thanksgiving, Smith showed up at the practice facility and headed right back home, the final piece of the puzzle that convinced Courtney to tell her husband he needed to leave his team and go to a mental-health facility in Colorado. Before he left, Smith told the rest of the offensive linemen and the coaches exactly what had been going on throughout the season, and the Colts responded by protecting and supporting the man who has been a pillar of the offensive line since 2018. Smith started 12 games and played 731 snaps last season. But he was far from the player he could be. 'Last year, I was just kind of out there,' Smith said. 'I was going through the motions, but I didn't feel that edge that players have. I didn't have that last year. I didn't feel that.' Smith hasn't been able to be himself in years. Before the scrupulosity took over Smith's life last year, he played through a painful knee injury in 2023, an injury that cost him seven games and ultimately forced him to undergo surgery on the joint. Physically, Smith feels better than he has in years. Mentally, it's possible that Smith feels better than he ever has before. When Smith first started going to therapy last fall, his psychologist told Courtney he could trace her husband's OCD back to at least the third grade, if not before that. For the first time, Smith believes he understands his OCD and has a handle on his condition. 'Instead of obsessing over other things, I can obsess about my craft,' Smith said. 'Turn a negative into the positive.' When Smith first talked about his battle with OCD in April, Courtney said she believed her husband could finally be the person he's meant to be. Half a year later, Smith has no reason to believe anything has changed since then. 'This is probably the best I've felt in a really long time,' Smith said. 'It's kind of nice to see everything come together. Now, I can just go play football.' For the love of the game alone.

A drug carrying the FDA's most serious warning recalled by a Florida company
A drug carrying the FDA's most serious warning recalled by a Florida company

Miami Herald

time24-07-2025

  • Miami Herald

A drug carrying the FDA's most serious warning recalled by a Florida company

A pharmaceutical company based in Naples with research and development division based in Coral Springs recalled a drug for failing an in-house testing of medication degradation. Lupin Pharmaceuticals' Clomipramine Hydrochloride capsules are used 'for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD),' according to the National Library of Medicine. The 2,724 recalled 100-count bottles of 25 mg capsules come from lot No. M300464 with an expiration date of June 2025. Lupin issued no press release for the June 27 recall. READ MORE: The role fake Viagra played in a 70-year-old Miami doctor losing his license Clomipramine also counts as an antidepressant and carries an FDA 'Black Box Warning' or 'Boxed Warning' on the packaging that begins: 'Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.' If you experience a medical problem because of this or any other drug, first notify a medical professional. Then tell the FDA via the MedWatch program, either online or by calling 800-332-1088.

Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Yahoo

time17-07-2025

  • Yahoo

Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" report provides a comprehensive insight into worldwide OCD clinical trials. It covers trial numbers, average enrollment, regional data, and sponsor types, enhanced by the proprietary Pharma database. Ideal for strategic decision-making and identifying competitive opportunities. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" clinical trials has been added to offering. The clinical trial report provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Obsessive-Compulsive Disorder Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Appendix Competitive Landscape Roche Holding AG Pfizer Inc Viatris Inc The Lundbeck Foundation Torrent Investments Pvt Ltd Syneos Health Inc AbbVie Inc AstraZeneca Plc Sandoz Group AG Byondis BV For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store